Postgres Vision 2021 Agenda to Include Top PostgreSQL Experts and Users from Around the World
26.5.2021 14:30:00 EEST | Business Wire | Press release
EDB, a leading contributor to PostgreSQL®, released the full speaker lineup for Postgres® Vision 2021. The annual event will take place virtually on June 22 and 23. Suzette Kent, former Federal CIO, will deliver the keynote address, discussing public and private digital transformations, followed by a keynote by Ed Boyajian, president and CEO of EDB, on Postgres as the future of technology and business. Registration for the two-day event is free and is available here.
The Future is Postgres
Postgres continues to rocket in popularity, offering the critical maturity that enterprises need to transform their businesses. In 2020, Postgres was recognized as Database Management System (DBMS) of 2020, and is one of the most commonly used and loved database management systems by developers worldwide.
Postgres Vision is the leading enterprise-focused Postgres event. Last year, it was the single largest Postgres conference with over 4,000 registrants. The Postgres Vision 2021 theme is “The Future is Postgres” and will feature sessions spanning global time zones, with speakers from organizations such as ACI Worldwide, Ericsson, and Borsa Italiana.
“Postgres is the most transformative open source technology in the world today,” said EDB president and CEO, Ed Boyajian. “At Postgres Vision, IT leaders, developers, DBAs, and others will learn why the most successful enterprises are choosing Postgres over other databases and platforms to reclaim control of their data.”
Agenda and Tracks
Postgres Vision 2021 will feature tracks covering the use of PostgreSQL in the enterprise, PostgreSQL and emerging technologies like Kubernetes and hybrid cloud, as well as developer focused topics, such as AI and machine learning. A PostgreSQL community track will cover real-world examples, PostgreSQL feature updates, and technical guidance.
Session highlights include:
- Suzette Kent, former Federal chief information officer, will begin the two-day event with a keynote address, where she’ll share her real-world experiences using open source and cloud technologies for global digital transformation.
- Ed Boyajian, president and CEO of EDB, will share a keynote address on the explosive growth of Postgres and why enterprises are choosing it to transform their businesses.
- Priyanka Sharma, general manager, Cloud Native Computing Foundation (CNCF), will talk about cloud native computing models in the enterprise.
- Ron Miller, enterprise reporter, TechCrunch, will lead a panel discussion on the future of data in a cloud native world.
- Bruce Momjian, vice president, Postgres evangelist, EDB, will discuss Data Horizons with Postgres.
View the full agenda for the Postgres Vision 2021 virtual event.
Registration
Join Postgres Vision 2021 virtually from anywhere in the world by registering today for free.
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres is a trademark of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005176/en/
Contact information
Emily White
PAN Communications
518-331-0131
enterprisedb@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
